Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the efficacy of NewGam in preventing serious bacterial infections, and on quality of life. The safety and pharmacokinetic profile of NewGam will also be evaluated.


Clinical Trial Description

NewGam is a new 10% human normal immunoglobulin (IVIG) solution developed by Octapharma for intravenous administration. It is supplied as a liquid formulation ready to use. IVIG has proved to be useful in a variety of clinical conditions other than for replacement of immunoglobulins, in which IVIG exhibits an immunomodulatory effect. Children and adults with PID have an increased risk of getting recurrent bacterial and viral infections that typically attack the respiratory tract (sinusitis, bronchitis, pneumonia) but can also affect the gastrointestinal tract (gastroenteritis). They can be severe and can lead to substantial morbidity. Responses to antibacterial therapy are often poor. At present, most primary immune deficiencies are not curable, but IVIGs have been shown to decrease the total number of severe infections and the duration of hospitalization. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01012323
Study type Interventional
Source Octapharma
Contact
Status Completed
Phase Phase 3
Start date November 2009
Completion date August 2012

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05621876 - Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia
Not yet recruiting NCT05758506 - Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan
Recruiting NCT05236764 - Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion N/A
Recruiting NCT05999422 - Exercise Capacity, Physical Activity Level and Quality of Life in Children With Primary Immunodeficiency